SCHEMBL9707078

SCHEMBL9707078

O=C(O)[C@@H]1CCCN1C(=O)CCSc1cc(Cl)c(O)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACE P12821 9/20 0.49
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
ACE2 Q9BYF1 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
F2 P00734 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9707114 0.86 ALDH1A1 (0.50) ACENPC1RAB9ACYP1A2CYP3A4
SCHEMBL11547220 0.83 NPC1 (0.59) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL9707098 0.83 ACE (0.43) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL9707052 0.82 ACE (0.46) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL9707178 0.77 RAB9A (0.63) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL11545636 0.76 KDM4E (0.53) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL11544959 0.75 DPP4 (0.49) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL6788316 0.74 ACE (0.62) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL6788307 0.74 ACE (0.62) ACECHRM2CHRM4CHRM1CHRM3
SCHEMBL10351951 0.74 L3MBTL1 (0.43) NPC1RAB9ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0190685-B1 HETEROCYCLIC AMIDES G.D. Searle & Co. (US) 1992-07-01 EP disclosed
US-4959364-A Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides G. D. SEARLE & CO. (US) 1990-09-25 US disclosed